Ribo Biopharma Advances AI-Driven siRNA Drug Development with Pheiron Collaboration, Highlights Progress in IPO Prospectus

Ribo Life Science and its subsidiary Ribocure Pharmaceuticals AB (Ribocure) are pleased to announce that the first two milestones of their strategic collaboration have been successfully achieved, marking a significant advancement for Ribo Life Science in the field of AI-assisted siRNA drug development.

Ribo Life Science and Pheiron's collaboration highlights the shared commitment to utilizing AI for analyzing large-scale human biomedical data, enhancing the ability to discover new targets and optimize clinical design. This partnership sets a new benchmark for the innovative development of AI technology in the biotech and pharmaceutical industries. The collaboration has already completed AI-supported systematic in-depth analyses of multiple candidate targets, improving the efficiency of developing high-quality innovative pipelines.

      Global Clinical Development Leader of Ribo Life ScienceAnders GabrielsenRepresentation:“"We are very satisfied with the Pheiron team and the collaboration with their AI technology platform. Based on this, we will further develop a target prioritization decision system and clinical development pathway based on patients' genetic information, biomarkers, and phenotypic characteristics. The new phase of AI-guided clinical development has indeed arrived."

     PheironChief Executive Officer (CEO)Thore BuergelRepresentation:“We are thrilled to continue our collaboration with the outstanding teams at Ribo Life Science and Ribocure in the field of RNA therapeutics. As the first generation capable of deeply and extensively measuring human biological characteristics, we are now presented with an unprecedented opportunity: making decisions based on real human data. This will accelerate progress, reduce translational risks, and increase the likelihood of project success."